Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 735615, 18 pages
http://dx.doi.org/10.1155/2015/735615
Review Article

Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder

1Department of Internal Medicine and Biomedicine, University of Palermo, 90100 Palermo, Italy
2Department of Human Pathology, University of Messina, 98125 Messina, Italy
3IFC CNR, Messina Unit, 98100 Messina, Italy
4Infectious Diseases Unit, Papardo-Piemonte Hospital, 98125 Messina, Italy
5AILMI-ONLUS Italian Association for the Control of Infectious Diseases, University of Messina, 98125 Messina, Italy

Received 19 November 2014; Revised 18 February 2015; Accepted 2 March 2015

Academic Editor: Daniel Teta

Copyright © 2015 Pasquale Mansueto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Palella Jr., R. K. Baker, A. C. Moorman et al., “Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Maartens, C. Celum, and S. R. Lewin, “HIV infection: epidemiology, pathogenesis, treatment, and prevention,” The Lancet, vol. 384, no. 9939, pp. 258–271, 2014. View at Publisher · View at Google Scholar
  3. T. A. Rasmussen, M. Tolstrup, C. R. Brinkmann et al., “Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial,” The Lancet, vol. 1, no. 1, pp. e13–e21, 2014. View at Publisher · View at Google Scholar
  4. S. G. Deeks, S. R. Lewin, and D. V. Havlir, “The end of AIDS: HIV infection as a chronic disease,” The Lancet, vol. 382, no. 9903, pp. 1525–1533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Lake and J. S. Currier, “Metabolic disease in HIV infection,” The Lancet Infectious Diseases, vol. 13, no. 11, pp. 964–975, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. V. A. Triant, “Cardiovascular disease and HIV infection,” Current HIV/AIDS Reports, vol. 10, no. 3, pp. 199–206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Appay and D. Sauce, “Immune activation and inflammation in HIV-1 infection: causes and consequences,” The Journal of Pathology, vol. 214, no. 2, pp. 231–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Aberg, “Aging, inflammation, and HIV infection,” Topics in Antiviral Medicine, vol. 20, no. 3, pp. 101–105, 2012. View at Google Scholar · View at Scopus
  9. D. E. Nixon and A. L. Landay, “Biomarkers of immune dysfunction in HIV,” Current Opinion in HIV and AIDS, vol. 5, no. 6, pp. 498–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. N. T. Funderburg, “Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients,” Current Opinion in HIV and AIDS, vol. 9, no. 1, pp. 80–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. National Center for Health Statistics, Centers for Disease Control and Prevention, National health and nutrition examination survey, 2014, http://www.cdc.gov/nchs/nhanes/about_nhanes.htm.
  12. A. R. Eckard, T. Leong, A. Avery et al., “Short communication: high prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women,” AIDS Research and Human Retroviruses, vol. 29, no. 9, pp. 1224–1228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mehta, E. Giovannucci, F. M. Mugusi et al., “Vitamin D status of HIV-infected women and its association with hiv disease progression, anemia, and mortality,” PLoS ONE, vol. 5, no. 1, Article ID e8770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. D. H. Watts, “Treating HIV during pregnancy: an update on safety issues,” Drug Safety, vol. 29, no. 6, pp. 467–490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Aziz, B. Livak, J. Burke-Miller et al., “Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART,” AIDS, vol. 27, no. 4, pp. 573–578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. Ross, S. Judd, M. Kumari et al., “Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals,” Antiviral Therapy, vol. 16, no. 4, pp. 555–563, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Wasserman and D. S. Rubin, “Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care,” AIDS Patient Care and STDs, vol. 24, no. 4, pp. 223–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Gedela, S. G. Edwards, P. Benn, and A. D. Grant, “Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-naïve patients in a single centre study,” International Journal of STD & AIDS, vol. 25, no. 7, pp. 488–492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. M. Arpadi, D. McMahon, E. J. Abrams et al., “Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents,” Pediatrics, vol. 123, no. 1, pp. e121–e126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kakalia, E. B. Sochett, D. Stephens, E. Assor, S. E. Read, and A. Bitnun, “Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus,” The Journal of Pediatrics, vol. 159, no. 6, pp. 951–957, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-P. Viard, J.-C. Souberbielle, O. Kirk et al., “Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study,” AIDS, vol. 25, no. 10, pp. 1305–1315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. V. L. Vecchi, M. Soresi, L. Giannitrapani et al., “Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected mediterranean subjects,” BMC Infectious Diseases, vol. 12, article 192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. N. Dao, P. Patel, E. T. Overton et al., “Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population,” Clinical Infectious Diseases, vol. 52, no. 3, pp. 396–405, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Havers, L. Smeaton, N. Gupte et al., “5-hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings,” The Journal of Infectious Diseases, vol. 210, no. 2, pp. 244–253, 2014. View at Publisher · View at Google Scholar
  25. A. A. Lambert, M. B. Drummond, S. H. Mehta et al., “Risk factors for vitamin D deficiency among hiv-infected and uninfected injection drug users,” PLoS ONE, vol. 9, no. 4, Article ID e95802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. C. E. Cherubin and J. D. Sapira, “The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later,” Annals of Internal Medicine, vol. 119, no. 10, pp. 1017–1028, 1993. View at Publisher · View at Google Scholar · View at Scopus
  27. L. S. Kahn, N. Satchidanand, A. Kopparapu, W. Goh, S. Yale, and C. H. Fox, “High prevalence of undetected vitamin D deficiency in an urban minority primary care practice,” Journal of the National Medical Association, vol. 103, no. 5, pp. 407–411, 2011. View at Google Scholar · View at Scopus
  28. M. Guidi, G. Foletti, P. McLaren et al., “Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry,” Antiviral Therapy, 2014. View at Publisher · View at Google Scholar
  29. M. Theodorou, T. Sersté, M. Van Gossum, and S. Dewit, “Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients,” Clinical Nutrition, vol. 33, no. 2, pp. 274–279, 2014. View at Publisher · View at Google Scholar
  30. D. A. Wohl, C. Orkin, M. Doroana et al., “Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO),” Antiviral Therapy, vol. 19, no. 2, pp. 191–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Hariparsad, S. C. Nallani, R. S. Sane, D. J. Buckley, A. R. Buckley, and P. B. Desai, “Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital,” Journal of Clinical Pharmacology, vol. 44, no. 11, pp. 1273–1281, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. T. T. Brown and G. A. McComsey, “Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D,” Antiviral Therapy, vol. 15, no. 3, pp. 425–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ellfolk, M. Norlin, K. Gyllensten, and K. Wikvall, “Regulation of human vitamin D3 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells,” Molecular Pharmacology, vol. 75, no. 6, pp. 1392–1399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Bozzette, C. F. Ake, H. K. Tam, S. W. Chang, and T. A. Louis, “Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 348, no. 8, pp. 702–710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Friis-Møller, P. Reiss, C. A. Sabin et al., “Class of antiretroviral drugs and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 356, no. 17, pp. 1723–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Grunfeld, J. A. Delaney, C. Wanke et al., “Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study,” AIDS, vol. 23, no. 14, pp. 1841–1849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Y. Hsue, P. W. Hunt, A. Schnell et al., “Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis,” AIDS, vol. 23, no. 9, pp. 1059–1067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. M. Crowe, C. L. V. Westhorpe, N. Mukhamedova, A. Jaworowski, D. Sviridov, and M. Bukrinsky, “The macrophage: the intersection between HIV infection and atherosclerosis,” Journal of Leukocyte Biology, vol. 87, no. 4, pp. 589–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Friis-Moller, R. Weber, P. Reiss, R. Thiebaut, O. Kirk, and A. d'Arminio Monforte, “Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study,” AIDS, vol. 17, no. 8, pp. 1179–1193, 2003. View at Google Scholar
  40. M. Galli, A. L. Ridolfo, F. Adorni et al., “Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 1, pp. 21–31, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. J. L. Anderson, H. T. May, B. D. Horne et al., “Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population,” The American Journal of Cardiology, vol. 106, no. 7, pp. 963–968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. G. Pittas, M. Chung, T. Trikalinos et al., “Systematic review: vitamin D and cardiometabolic outcomes,” Annals of Internal Medicine, vol. 152, no. 5, pp. 307–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Santoro, G. Gagliostro, A. Alibrandi et al., “Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease,” Nutrients, vol. 6, no. 3, pp. 1029–1037, 2014. View at Publisher · View at Google Scholar
  44. A. Vaidya and J. S. Williams, “The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes,” Metabolism: Clinical and Experimental, vol. 61, no. 4, pp. 450–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. A. I. Choi, J. C. Lo, K. Mulligan et al., “Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons,” Clinical Infectious Diseases, vol. 52, no. 7, pp. 941–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Portilla, O. Moreno-Perez, C. Serna-Candel et al., “Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV,” Journal of the International AIDS Society, vol. 17, no. 1, Article ID 18945, 2014. View at Publisher · View at Google Scholar
  47. H. Lai, E. K. Fishman, G. Gerstenblith et al., “Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defined cardiovascular risk,” Vascular Health and Risk Management, vol. 9, no. 1, pp. 729–737, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Tebas, “Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options,” Journal of Acquired Immune Deficiency Syndromes, vol. 49, supplement 2, pp. S86–S92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Khan, S. Kunutsor, O. H. Franco, and R. Chowdhury, “Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies,” The Proceedings of the Nutrition Society, vol. 72, no. 1, pp. 89–97, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Szep, G. Guaraldi, S. S. Shah et al., “Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection,” AIDS, vol. 25, no. 4, pp. 525–529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. O. M. Adeyemi, B. Livak, J. Orsi et al., “Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants,” AIDS Patient Care and STDs, vol. 27, no. 6, pp. 320–325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. C. J. P. van den Bout-van den Beukel, M. van den Bos, W. J. G. Oyen et al., “The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients,” HIV Medicine, vol. 9, no. 9, pp. 771–779, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. R. I. Connor and W. F. C. Rigby, “1α,25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1,” Biochemical and Biophysical Research Communications, vol. 176, no. 2, pp. 852–859, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Schuitemaker, N. A. Kootstra, M. H. G. M. Koppelman et al., “Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages,” The Journal of Clinical Investigation, vol. 89, no. 4, pp. 1154–1160, 1992. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Haug, F. Müller, P. Aukrust, and S. S. Fræland, “Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival,” The Journal of Infectious Diseases, vol. 169, no. 4, pp. 889–893, 1994. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Teichmann, E. Stephan, T. Discher et al., “Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection,” Metabolism: Clinical and Experimental, vol. 49, no. 9, pp. 1134–1139, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Mehta, F. M. Mugusi, D. Spiegelman et al., “Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania,” AIDS Patient Care and STDs, vol. 25, no. 10, pp. 579–585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. J. E. Sherwood, O. C. Mesner, A. C. Weintrob et al., “Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort,” Clinical Infectious Diseases, vol. 55, no. 12, pp. 1727–1736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter, “The prevalence of hepatitis C virus infection in the United States, 1999 through 2002,” Annals of Internal Medicine, vol. 144, no. 10, pp. 705–714, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. F. J. Torriani, M. Rodriguez-Torres, J. K. Rockstroh et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients,” The New England Journal of Medicine, vol. 351, no. 5, pp. 438–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. H.-H. Thein, Q. Yi, G. J. Dore, and M. D. Krahn, “Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis,” AIDS, vol. 22, no. 15, pp. 1979–1991, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. M. W. Hull, K. Rollet, E. E. M. Moodie et al., “Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients,” AIDS, vol. 26, no. 14, pp. 1789–1794, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Collazos, J. A. Cartón, and V. Asensi, “Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus,” Current HIV Research, vol. 9, no. 5, pp. 339–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. L. M. Villar, J. A. Del Campo, I. Ranchal, E. Lampe, and M. Romero-Gomez, “Association between vitamin D and hepatitis C virus infection: a meta-analysis,” World Journal of Gastroenterology, vol. 19, no. 35, pp. 5917–5924, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Abramovitch, L. Dahan-Bachar, E. Sharvit et al., “Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats,” Gut, vol. 60, no. 12, pp. 1728–1737, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Milazzo, C. Mazzali, G. Bestetti et al., “Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population,” Current HIV Research, vol. 9, no. 3, pp. 186–193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Farnik, J. Bojunga, A. Berger et al., “Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients,” Hepatology, vol. 58, no. 4, pp. 1270–1276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Mandorfer, T. Reiberger, B. A. Payer et al., “Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients,” AIDS, vol. 27, no. 2, pp. 227–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. A. D. Branch, M. Kang, K. Hollabaugh, C. M. Wyatt, R. T. Chung, and M. J. Glesby, “In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use,” The American Journal of Clinical Nutrition, vol. 98, no. 2, pp. 423–429, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Abu-Mouch, Z. Fireman, J. Jarchovsky, A.-R. Zeina, and N. Assy, “Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients,” World Journal of Gastroenterology, vol. 17, no. 47, pp. 5184–5190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Gal-Tanamy, L. Bachmetov, A. Ravid et al., “Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes,” Hepatology, vol. 54, no. 5, pp. 1570–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Kondo, T. Kato, O. Kimura et al., “1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial,” PLoS ONE, vol. 8, no. 5, Article ID e63672, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. C. J. Murray, K. F. Ortblad, C. Guinovart et al., “Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013,” The Lancet, vol. 384, no. 9947, pp. 1005–1070, 2013. View at Publisher · View at Google Scholar
  74. S. D. Lawn, S. T. Butera, and T. M. Shinnick, “Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis,” Microbes and Infection, vol. 4, no. 6, pp. 635–646, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. K. B. Gibney, L. MacGregor, K. Leder et al., “Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa,” Clinical Infectious Diseases, vol. 46, no. 3, pp. 443–446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Rathored, S. K. Sharma, B. Singh et al., “Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D,” The International Journal of Tuberculosis and Lung Disease, vol. 16, no. 11, pp. 1522–1528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. A. R. Martineau, P. M. Timms, G. H. Bothamley et al., “High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial,” The Lancet, vol. 377, no. 9761, pp. 242–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. C. R. Sudfeld, E. L. Giovannucci, S. Isanaka et al., “Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected tanzanian adults initiating antiretroviral therapy,” The Journal of Infectious Diseases, vol. 207, no. 3, pp. 378–385, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. K. E. Nnoaham and A. Clarke, “Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis,” International Journal of Epidemiology, vol. 37, no. 1, pp. 113–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. M. A. French, M. S. King, J. M. Tschampa, B. A. Da Silva, and A. L. Landay, “Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T Cells,” Journal of Infectious Diseases, vol. 200, no. 8, pp. 1212–1215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. S. R. Ostrowski, T. L. Katzenstein, B. K. Pedersen, J. Gerstoft, and H. Ullum, “Residual viraemia in HIV-1-infected patients with plasma viral load 20 copies/ml is associated with increased blood levels of soluble immune activation markers,” Scandinavian Journal of Immunology, vol. 68, no. 6, pp. 652–660, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. D. A. Duprez, J. Neuhaus, L. H. Kuller et al., “Inflammation, coagulation and cardiovascular disease in HIV-infected individuals,” PLoS ONE, vol. 7, no. 9, Article ID e44454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. A. de Luca, K. de Gaetano Donati, M. Colafigli et al., “The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study,” BMC Infectious Diseases, vol. 13, no. 1, article 414, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. Á. H. Borges, M. J. Silverberg, D. Wentworth et al., “Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers,” AIDS, vol. 27, no. 9, pp. 1433–1441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Biron, C. Bobin-Dubigeon, C. Volteau et al., “Metabolic syndrome in french HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 28, no. 12, pp. 1672–1678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. A. C. Hearps, G. E. Martin, R. Rajasuriar, and S. M. Crowe, “Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing,” Current HIV/AIDS Reports, vol. 11, no. 1, pp. 20–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. K. W. Colston, L. C. Lowe, J. L. Mansi, and M. J. Campbell, “Vitamin D status and breast cancer risk,” Anticancer Research, vol. 26, no. 4, pp. 2573–2580, 2006. View at Google Scholar · View at Scopus
  88. T. Mizoue, Y. Kimura, K. Toyomura et al., “Calcium, dairy foods, vitamin D, and colorectal cancer risk: the fukuoka colorectal cancer study,” Cancer Epidemiology Biomarkers & Prevention, vol. 17, no. 10, pp. 2800–2807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Bakhru, J. B. Mallinger, R. J. Buckanovich, and J. J. Griggs, “Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: a study from the NHANES,” Gynecologic Oncology, vol. 119, no. 2, pp. 314–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. G. G. Schwartz, “Vitamin D and intervention trials in prostate cancer: from theory to therapy,” Annals of Epidemiology, vol. 19, no. 2, pp. 96–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. K. M. Erlandson, I. Gudza, S. Fiorillo et al., “Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe,” International Journal of Infectious Diseases, vol. 24, pp. 6–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. EACSEACSgpamon-iciHOA, 2014, http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf.
  93. G. A. McComsey, P. Tebas, E. Shane et al., “Bone disease in HIV infection: a practical review and recommendations for HIV care providers,” Clinical Infectious Diseases, vol. 51, no. 8, pp. 937–946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Chung, J. Lee, T. Terasawa, J. Lau, and T. A. Trikalinos, “Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. preventive services task force,” Annals of Internal Medicine, vol. 155, no. 12, pp. 827–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. M. F. Holick, “Medical progress: vitamin D deficiency,” The New England Journal of Medicine, vol. 357, no. 3, pp. 266–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. V. Groleau, R. A. Herold, J. I. Schall et al., “Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV,” Journal of Pediatric Gastroenterology & Nutrition, vol. 56, no. 3, pp. 311–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. A. S. Ettinger, H. Lamadrid-Figueroa, M. M. Téllez-Rojo et al., “Effect of calcium supplementation on blood lead levels in pregnancy: a randomized placebo-controlled trial,” Environmental Health Perspectives, vol. 117, no. 1, pp. 26–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. C. T. Longenecker, C. O. Hileman, T. L. Carman et al., “Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial,” Antiviral Therapy, vol. 17, no. 4, pp. 613–621, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. V. Giacomet, A. Vigano, V. Manfredini et al., “Cholecalciferol supplementation in HIV-infected youth with vitamin d insufficiency: effects on vitamin d status and t-cell phenotype: a randomized controlled trial,” HIV Clinical Trials, vol. 14, no. 2, pp. 51–60, 2013. View at Publisher · View at Google Scholar · View at Scopus